Largest Biomedical IPO of 2020: RemeGen

Largest Biomedical IPO of 2020: RemeGen

New drug approval: Telitacicept On March 12, the State Food and Drug Administration in China issued an announcement, authorizing conditional approval for RemeGen’s therapeutic biological product for injection, Telitacicept. The drug is an innovative drug TACl-Fc...
Top-tier Chinese Pharmaceutical company profile: BeiGene

Top-tier Chinese Pharmaceutical company profile: BeiGene

BeiGene Co., Ltd   2019 Revenue: US$ 428.21 million Number of Employees: 4,200+ Founded: 2010 Overview BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to...